
    PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION, Plaintiff v. Leslie RUTLEDGE, in her official capacity as Attorney General of the State of Arkansas, Defendant
    CASE NO. 4:15-CV-00510 BSM
    United States District Court, E.D. Arkansas, Western Division.
    Signed 03/01/2017
    
      Andrew W. London, Catherine Deneke, Dean Richlin, Kristyn Marie- DeFilipp, Foley Hoag LLP, Boston, MA, Lyn Peeples Pruitt, Mitchell, Williams, Selig, Gates & Woodyard, P.L.L.C., Little Rock, AR, for Plaintiff.
    Shawn J. Johnson, Sarah R. Tacker, Arkansas Attorney General’s Office, Little Rock, AR, for Defendant.
   ORDER

BRIAN S. MILLER, UNITED STATES DISTRICT JUDGE

Plaintiff Pharmaceutical Care Management Associations’s (PCMA) motion for summary judgment [Doc. No.'75] is granted in part and denied in part, and defendant Leslie Rutledge’s (State of Arkansas) motion for summary judgment [Doc. No. 77] is granted in part and denied in part. The joint motions to extend time [Doc. Nos. 103,104] are denied as moot, and this case is dismissed with prejudice.

I. BACKGROUND

Independent community pharmacies have had to eliminate employees during the last five to ten years due to the financial hardships they have faced. PL’s Resp. Def.’s Statement Material Fact ¶¶ 18, 22-24, 28, 44, Doc. No. 85-1. The Arkansas legislature passed and amended Arkansas Code Annotated section 17-92-507 et seq. in an attempt to address this issue. Act 1194 was passed in 2013 to “Provide for the Transparency of Maximum Allowable Cost Lists for Prescription Drugs,” S.B. 1138, 89th Gen. Assemb., Reg. Sess. (Ar. 2013), and Act 900 was passed in 2015 to “Amend the Laws Regarding Maximum Allowable Cost Lists; and to Create Accountability in the Establishment of Prescription Drug Pricing.” S.B. 688, 90th Gen. Assemb., Reg. Sess. (Ar. 2015).

A. Act 900 of 2015

Act 900 amended Act 1194 in a number of ways. First, it defines “[pjharmacy acquisition cost” as “the amount that a pharmaceutical wholesaler charges for a pharmaceutical product as listed on the pharmacy’s billing invoice.” Ark. Code Ann. § 17-92-507(a)(6). Second, it provides that a pharmacy benefits manager (“PBM”) must:

[u]pdate its Maximum Allowable Cost List on a timely basis, but in no event longer than seven (7) calendar days from an increase of ten percent (10%) or more in the pharmacy acquisition cost from sixty percent (60%) or more of the pharmaceutical wholesaler doing business in the state or a change in the methodology on which the Maximum Allowable Cost List is based or in the value of a variable involved in the methodology.

Id. § 507(c)(2). Third, it requires a PBM to:

Provide a reasonable administrative appeal procedure to allow pharmacies to challenge maximum allowable costs and reimbursements made under a maximum allowable cost for a specific drug or drugs as: (a) not meeting the requirement of this section or (b) being below the pharmacy acquisition cost.

Id. § 507(c)(4)(A)(i). Fourth, it requires PBMs to permit the challenging pharmacy to reverse and rebill each claim affected by the inability to procure the drug at a cost that is equal to or less than the cost on the relevant maximum allowable cost (“MAC”) list where the drug is not available “below the pharmacy acquisition cost from the pharmaceutical wholesaler from whom the pharmacy or pharmacist purchases the majority of prescription drugs for resale.” Id. § 507(c)(4)(C)(iii). Fifth, it provides that a

pharmacy or pharmacist may decline to provide the pharmacy services to a patient or pharmacy benefits manager if, as a result of a Maximum Allowable Cost List, a pharmacy or pharmacist is to be paid less than the pharmacy acquisition cost of the pharmacy providing pharmacist services.

Id. § 17-92-507(e) (commonly known as the “decline-to-dispense” provision).

B. PCMA, MAC Lists, and Pharmaceutical Reimbursement Scheme

PCMA is a national trade association representing the eleven largest PBMs in the country. Def.’s Resp. Pl.’s Statement Material Fact ¶ 1, Doc. No. 89. None of PCMA’s member PBMs are incorporated in Arkansas, but they have contracts covering beneficiaries in Arkansas. Id. ¶ 19.

PBMs act as intermediaries between health plans and pharmacies. Generally, when a patient is prescribed a drug by a physician, the patient presents the prescription to a pharmacist. The pharmacist, who buys drugs from wholesalers, dispenses the drug to the patient. Often, the patient does not pay the full price that the pharmacist receives for the drug but instead pays a portion, or copay, if the patient is a member of a health plan that covers part of the drug’s cost.

The market for purchasing prescription drugs is national, id. ¶ 21, and PBMs perform such services as' processing claims, generating reports and data, and managing clinical and financial information as well as retail and mail-order drug sales. Pl.’s Resp. Def.’s Statement Material Fact ¶ 5. PBMs also calculate benefit levels and make disbursements. Def.’s Resp. Pl.’s Statement Material Fact ¶ 2. To carry out these services, PBMs aggregate market data to create confidential maximum allowable cost (“MAC”) lists. MAC lists are used to set reimbursement rates for pharmacies filling generic prescriptions. Wholesaler pricing information is one type of data used by PBMs to create MAC lists. Pl.’s Resp. Def.’s Statement Material Fact ¶ 69. This information is available through pricing guides such as Medispan and, in some cases, is made available by wholesalers. Id. ¶¶ 69-71.

Contracts between PBMs and pharmacies create pharmacy networks. Def.’s Resp. Pl.’s Statement Material Fact ¶ 12. These contracts generally require pharmacies to fill prescriptions and dispense prescription medications regardless of the amount that the pharmacy will be reimbursed. Pl.’s Resp. Def.’s Statement Material Fact ¶81. These contracts also allow pharmacies to appeal unfavorable reimbursement decisions. Id. ¶ 75. PBMs often select pharmacies willing to take lower reimbursements in exchange for being placed in a preferred network and receiving patronage from beneficiaries of the plans serviced by the PBMs. Id. ¶ 80; Defi’s Resp. PL’s Statement Material Fact ¶ 13.

C. PCMA’s Challenge to Act 900

PCMA challenges Act 900 claiming that it (1) is preempted by ERISA; (2) is preempted by Medicare Part D; (3) violates the Commerce Clause of the United States Constitution; (4) violates the Contract Clauses of the United States Constitution and the Arkansas Constitution; and (5) is so vague as to violate the Due Process Clauses of the United States Constitution and the Arkansas Constitution. Both parties move for summary judgment on all claims.

II. LEGAL STANDARD

Summary judgment is appropriate when there is no genuine dispute as to any material fact and the moving party is entitled to judgment as a matter of law. See Fed. R. Civ. P. 56(a); Anderson v. Liberty Lobby Inc., 477 U.S. 242, 249-50, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). Once the moving party demonstrates that there is no genuine dispute of material fact, the nonmoving party may not rest upon the mere allegations or denials in the pleadings. Holden v. Hirner, 663 F.3d 336, 340 (8th Cir. 2011). Instead, the nonmoving party must produce admissible evidence demonstrating a genuine factual dispute that requires resolution at trial. Id. Importantly, when considering a motion for summary judgment, all reasonable inferences must be drawn in a light most favorable to the nonmoving party. Holland v. Sam’s Club, 487 F.3d 641, 643 (8th Cir. 2007). When both parties move for summary judgment, all justifiable inferences must be drawn in favor of the losing party. Murphy Expl. & Prod. Co. v. Oryx Energy Co., 101 F.3d 670, 673 (Fed. Cir. 1996). The evidence is not weighed, and no credibility determinations are made. Jenkins v. Winter, 540 F.3d 742, 750 (8th Cir. 2008).

III. DISCUSSION

A. ERISA Preemption

PCMA’s motion for summary judgment is granted on its claim that Act 900 is ERISA preempted, and the State of Arkansas’s motion is denied because Act 900 is invalid as applied to PBMs in their administration and management of ERISA plans.

Initially, a decision consistent with that reached by the Southern District of Iowa in Pharmaceutical Care Management Association v. Gerhart, No. 4:14-CV-000345, 2015 WL 10767327 (S.D. Iowa Sept. 8, 2015) was reached. The Southern District of Iowa and this court independently reached the same conclusions when analyzing similar statutes. Iowa Code section 510B.8 is similar to Act 900 in a number of ways, and the Northern District of Iowa held that the Iowa statute’ was not preempted by ERISA. While preparing this order, however, the Eighth Circuit Court of Appeals reversed the Southern District of Iowa. See Pharm. Care Mgmt. Ass’n v. Gerhart, 852 F.3d 722 (8th Cir. 2017) reh’g denied. In that the Eighth Circuit’s opinion controls, this ruling has been revised’ to conform to that opinion.

In Gerhart, the Eighth Circuit held that Iowa Code section 510B.8, which is similar to Act 900 in many of the ways that it regulates PBMs and MAC pricing, is preempted by ERISA because it interferes with nationally uniform plan’ administration. Gerhart held that the Iowa statute interferes with uniform plan' administration by requiring PBMs, as third-party administrators, to provide a procedure by which pharmacies can contest and appeal MAC reimbursements because doing so restricts an administrator’s control in the calculation of drug benefits and removes the ability to conclusively determine final drug benefit payments and monitor funds. See id., 852 F.3d at 730-31. Similarly, section 507(c)(4) of Act 900 requires PBMs to provide a “reasonable administrative appeal procedure” that allows pharmacies to challenge MAC costs and to reverse and rebill the claim in question.

Gerhart also held that the Iowa law interferes with uniform plan administration by restricting the class of drugs PBMs may place on MAC lists and by restricting the sources from which PBMs may obtain pricing information because both restrictions interfere with the calculation of benefit levels and with making disbursements. 852 F.3d at 730-31. Section 507(b) of Act 900, likewise, restricts the class of drugs PBMs may place on its MAC lists. Act 900 does not limit the sources from which PBMs may obtain pricing information per se, but sections 507(c)(2) and (c)(4) set “pharmacy acquisition cost” as the standard by which PBMs must update MAC lists and grant appeals, which is as intrusive with MAC methodology as the Iowa statute.

Finally, Gerhart held that the Iowa statute interferes with uniform plan administration by requiring PBMs to report or disclose to pharmacies the economic bases of its MAC lists. 852 F.3d at 730-31. Section 507(c) of Act 900 requires PBMs to provide their MAC lists to pharmacies, to promptly notify pharmacies when MAC lists are updated, and to disclose to pharmacies certain sourcing and pricing information when an appeal is denied.

Because Act 900 regulates PBMs in ways fundamentally similar to the Iowa statute in Gerhart, Act 900 is preempted by ERISA. See 852 F.3d at 731-32. Preemption, however, only requires “invalidation of [Act 900] as applied to PBMs in their administration and management of prescription drug benefits for ERISÁ plans.” See id. (citing Gobeille v. Liberty Mut. Ins. Co., — U.S. -, 136 S.Ct. 936, 943, 194 L.Ed.2d 20 (2016) (concluding that Vermont’s regime is preempted “as applied to ERISA plans”)). Thus, the remainder of PCMA’s claims must also be evaluated.

B. Medicare Part D Preemption

The State of Arkansas’s motion for summary judgment is granted on PCMA’s Medicare Part D preemption argument, and PCMA’s motion is denied because Act 900 does not act with respect to a standard established under Medicare Part D.

The Medicare statute provides that “[t]he standards established under this part shall supersede any State law or regulation ... with respect to [Part D] plans which are offered by [Part D] organizations under this part.” 42 U.S.C. § 1395w-26(b)(3) (incorporating Part .C’s preemption provision, 42 U.S.C, § 1395w-112(g)). A “standard” within the meaning of this preemption provision means a statutory provision or a regulation promulgated under Medicare and published in the Code of Federal Regulations. Do Sung Uhm v. Humana, Inc., 620 F.3d 1134, 1148 n. 20 (9th Cir. 2010). The meaning of the phrase “with respect to” is broad. For a law to act “with respect .to” a Medicare standard, it need not exclusively impact a Medicare standard, and it need not be inconsistent with a Medicare standard. Id. at 1149, 1150 n. 25. Ultimately, preemption is found “only where it is the ‘clear and manifest purpose of Congress,’” and the plain language of the preemption clause offers the best evidence of Congress’s preemptive intent. Id. at 1148 (quoting Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230, 67 S.Ct. 1146, 91 L.Ed. 1447 (1947)).

PCMA asserts that Act 900 acts with respect to Part D’s “negotiated prices” standard, which requires beneficiaries to have access to “negotiated prices.” 42 U.S.C. § 1395w-102(d). The regulations accompanying this provision define “negotiated prices” as “prices for covered Part D drugs that ... the Part D sponsor (or other intermediary contracting organization) and the network dispensing pharmacy ... have negotiated as the amount such network entity will receive, in total, for a particular drug.” 42 C.F.R. § 423.100.

Act 900’s regulation of MAC pricing does not act with respect to Part D’s negotiated prices standard because the standard . excludes “additional . contingent amounts” that “increase prices and cannot reasonably be determined at the point of sale.” See id. If Act 900 has any effect on the price of a drug, it would be to increase the price, and because the increase would be contingent on the outcome of a MAC appeal, it is a contingent amount not able to be determined at the point of sale. Thus, Act 900 does not act with respect to Part D’s negotiated prices standard because the Part D standard excludes it from its scope.

PCMA also asserts that Act 900’s decline-to-dispense provision acts with respect to Part D’s “standards' for convenient access to network pharmacies.” 42 C.F.R, § 423.120(a)(1). These standards require Part D sponsors to structure their networks so that certain percentages of beneficiaries live within certain distances of a network pharmacy. See id. Act 900’s decline-to-dispense provision does not act with respect to Part D’s pharmacy-access standards because a pharmacy that declines to dispense a drug in anticipation of a negative reimbursement is not thereby transformed into an out-of-network pharmacy.

C, The Dormant Commerce Clause

The State of Arkansas’s motion for summary judgment is granted on PCMA’s Commerce Clause, claim, and PCMA’s motion is denied because Act 900 does not discriminate against out-of-state economic interests in favor of in-state economic interests and because any burden it imposes on interstate commerce is not “clearly excessive in relation to the putative local benefits.” U & I Sanitation v. City of Columbus, 205 F.3d 1063, 1067 (8th Cir. 2000) (citing Pike v. Bruce Church, Inc., 397 U.S. 137, 142, 90 S.Ct. 844, 25 L.Ed.2d 174 (1970)).

The Commerce Clause, intended to create an area of free trade among the states, gives Congress the power to regulate interstate commerce. U.S. Const, art. I, § 8, cl. 3; McLeod v. J. E. Dilworth Co., 322 U.S. 327, 330, 64 S.Ct. 1023, 88 L.Ed. 1304 (1944). The negative, implication of this power, known as the dormant Commerce Clause, prohibits states from unjustifiably discriminating against interstate commerce. Wyoming v. Oklahoma, 502 U.S. 437, 453, 112 S.Ct. 789, 117 L.Ed.2d 1 (1992); Hampton Feedlot, Inc. v. Nixon, 249 F.3d 814, 818 (8th Cir. 2001). If a state law overtly discriminates, the state must show, “under rigorous scrutiny, that it has no other means to advance a legitimate local interest.” U & I Sanitation, 205 F.3d at 1067 (citing C & A Carbone, Inc. v. Town of Clarkstown, 511 U.S. 383, 392, 114 S.Ct. 1677, 128 L.Ed.2d 399 (1994)). Thus, a state law that overtly discriminates is presumed invalid. U & I Sanitation, 205 F.3d at 1063.

Act 900 does not overtly discriminate against interstate commerce. A law discriminates against interstate commerce when it “favors in-state economic interests over their out-of-state counterparts.” Oregon Waste Sys., Inc. v. Dep’t of Envtl. Quality of State of Oregon, 511 U.S. 93, 93, 114 S.Ct. 1345, 128 L.Ed.2d 13 (1994); Pete’s Brewing Co. v. Whitehead, 19 F.Supp.2d 1004, 1010 (W.D. Mo. 1998) (dormant Commerce Clause prohibits “regulatory measures designed to benefit in-state economic interests by burdening out-of-state competitors”). Act 900 imposes requirements on PBMs. It does not favor in-state PBMs over out-of-state PBMs or in-state pharmacies over out-of-state pharmacies.

PCMA asserts Act 900 creates impermissible economic protectionism in favor of pharmacies, but “[t]he fact that the burden of a state regulation falls on some interstate companies does not, by itself, establish a claim of discrimination against interstate commerce.” Exxon Corp. v. Governor of Maryland, 437 U.S. 117, 126, 98 S.Ct. 2207, 57 L.Ed.2d 91 (1978). The Commerce Clause does not protect particular structures or methods of operation in a market. Id. at 127-28, 98 S.Ct. 2207.

Notwithstanding its facially nondiscriminatory status, Act 900 still may incidentally burden interstate commerce. See Ben Oehrleins & Sons & Daughter, Inc. v. Hennepin Cty., 115 F.3d 1372, 1387 (8th Cir. 1997) (even nondiscriminatory laws may unconstitutionally burden interstate commerce). Even if it is accepted that Act 900 imposes some incidental burden on interstate commerce, PCMA must show that the burden clearly outweighs its putative, or presumed, local benefit. Pike, 397 U.S. at 142, 90 S.Ct. 844; U & I Sanitation, 205 F.3d at 1067. A state law that discriminates only incidentally, is presumed valid. R & M Oil & Supply, Inc. v. Saunders, 307 F.3d 731, 737 (8th Cir. 2002) (“State statutes passed for the protection of the public’s health and safety are generally constitutional despite the incidental burden they may impose on interstate commerce.”). Due to the strong presumption of validity, it is not for the courts to second-guess legislative judgment regarding the importance of legitimate safety justifications, Kassel v. Consol. Freightways Corp. of Delaware, 450 U.S. 662, 670, 101 S.Ct. 1309, 67 L.Ed.2d 580 (1981), unless “a statute provides little or nothing in the way of demonstrable legitimate local benefit.” Saunders, 307 F.3d at 737.

Act 900’s putative local benefit is legitimate. Independent community pharmacies in Arkansas are in economic distress, PL’s Resp. Def.’s Statement Material Fact ¶¶ 18, 22-24, 28, 44, and the parties agree that Act 900’s purpose is to protect pharmacies. See PL’s Mem. Supp. Summ. J., Doc. No. 75-1 at 26; Def.’s Reply Pl.’s Resp. Defi’s Mot. Summ. J. ¶ 14, Doc. No. 92. The parties agree that the Arkansas legislature considered whether unfair MAC methodologies are resulting in pharmacies closing down, especially in rural areas. The parties agree that approximately 44% of Arkansans live in rural areas. PL’s Resp. Def.’s Statement Material Fact ¶ 7. The parties agree that 70% to 90% of all prescriptions are for generic drugs, which utilize MAC pricing. Id. ¶ 12. They also agree that even large chain pharmacies, which are able to command more favorable contractual terms, report under-reimbursement from PBMs as a primary reason for poor financial performance. Id. ¶¶ 26, 77. Finally, other courts have recognized that states have a legitimate interest in preserving the health of their citizens by increasing access to prescription drugs. See Pham. Care Mgmt. Ass’n v. Rowe, 429 F.3d 294, 313-14 (1st Cir. 2005); Gerhart, 2015 WL 10767327 at *3-4 (a law designed to preserve the health of citizens was specifically aimed at preventing unfair practices of PBMs from “eroding local pharmacies”).

As for burdens, PCMA asserts that Act 900 forces PBMs to choose between applying a new, uniform business model nationwide; suffering administrative costs by adopting state-specific practices when doing business in Arkansas; or abstaining entirely from conducting business in Arkansas. The possible effects of Act 900 on the administrative costs or on the profits of PBMs is not a cognizable burden under the Commerce Clause, and even if it was, the burden to interstate commerce would not be clearly excessive relative to Act 900’s presumed local benefit. See Rowe, 429 F.3d at 313. PCMA also asserts Act 900 will ultimately harm the public because it will cause the cost of prescriptions to rise and make prescriptions less accessible, but Act 900 does not require PBMs to pass costs on to consumers. Further, this argument “relates to the wisdom of the statute, not to its burden on commerce.” Exxon Corp., 437 U.S. at 127, 98 S.Ct. 2207.

PCMA asserts that Act 900’s decline-to-dispense provision burdens interstate commerce because it will prevent people who are employed by companies outside the state from buying prescriptions at pharmacies inside the state. Even if this assertion is accepted as true, PCMA acknowledges that “pharmacies receive less than their acquisition cost in a very small number of prescriptions dispensed.” Pl.’s Statement Material Fact ¶ 10; Pl.’s Resp. Defi’s Statement Material Fact ¶ 40 (undisputed that pharmacists experience approximately 10% of reimbursements below cost). Act 900 also requires PBMs to timely update their MAC lists and to provide an appeals procedure, both of which further reduce the likelihood of negative reimbursements. For these reasons, Act 900’s burden on interstate commerce does not clearly outweigh its presumed local benefit.

D. State and Federal Contract Clauses

The State of Arkansas’s motion for summary judgment is granted, and PCMA’s motion is denied because Act 900 does not substantially impair preexisting contractual relations.

The United States Constitution and the Arkansas Constitution prohibit the passing of laws that impair the “obligation of contracts.” Consequently, these issues will be analyzed together. U.S. Const, art. I, § 10; Ark. Const, art. II, § 17; see E. Poinsett Cty. Sch. Dist. No. 14 v. Massey, 315 Ark. 163, 866 S.W.2d 369, 371 (1993); Mahurin v. Oaklawn Jockey Club, 299 Ark. 13, 771 S.W.2d 19, 21 (1989). Although the Contract Clause is facially absolute, states maintain the right to act pursuant to their inherent police power to promote the public welfare. Minnesota Ass’n of Health Care Facilities, Inc. v. Minnesota Dep’t of Pub. Welfare, 742 F.2d 442, 449 (8th Cir. 1984) (quoting Home Bldg. & Loan Ass’n v. Blaisdell, 290 U.S. 398, 428, 54 S.Ct. 231, 78 L.Ed. 413 (1934)). One whose rights are subject to legitimate state regulation cannot render such regulation illegitimate by making a contract about them. Hudson Cty. Water Co. v. McCarter, 209 U.S. 349, 357, 28 S.Ct. 529, 52 L.Ed. 828 (1908).

To violate the Contract Clause, a state law must substantially impair preexisting contractual relationships. Equipment Mfrs. Inst. v. Janklow, 300 F.3d 842, 849-50 (8th Cir. 2002). A law already in effect at the time a contract is entered does not violate the Contract Clause. Blaisdell, 290 U.S. at 429-30, 54 S.Ct. 231; Mahurin, 771 S.W.2d at 21; McGuire v. Ameritech Servs., Inc., 253 F.Supp.2d 988, 1006 (S.D. Ohio 2003). Act 900 went into effect July 22, 2015, so, as a matter of Jaw, it cannot impair contracts entered after that date.

PCMA asserts that Act 900 impairs contractual relations between both PBMs and pharmacies and between PBMs and their client health plans in the context , of MAC pricing, appeals, and guaranteed dispensing.. The record is unclear as to whether any unexpired contracts between PBMs and pharmacies or between PBMs and health plans, which were entered prior to July 22, 2015, still exist. Accordingly, a substantive Contract • Clause analysis follows.

Whether a contractual impairment is substantial depends primarily on the nature of the impairment and the extent to which it disrupts reasonable contractual expectations. Janklow, 300 F.3d at 854-55; Minnesota Ass’n of Health Care Facilities, 742 F.2d at 450. Past industry regulation plays a significant role in determining the parties’ reasonable contractual expectations. Id. The more severe the impairment, the closer the scrutiny applied. Id. Even a law that substantially impairs a preexisting contract does not violate the Contract Clause unless it lacks a significant and legitimate purpose or is an unreasonable method of accomplishing its purpose. See Janklow, 300 F.3d at 850; White Motor Corp. v. Malone, 599 F.2d 283, 287 (8th Cir. 1979), aff'd, Malone v. White Motor Corp., 444 U.S. 911, 100 S.Ct. 223, 62 L.Ed.2d 166 (1979). In the context of economic regulation, “courts properly defer to legislative judgment as to the necessity and reasonableness of a particular measure.” U.S. Trust Co. of N.Y. v. New Jersey, 431 U.S. 1, 22-23, 97 S.Ct. 1505, 52 L.Ed.2d 92 (1977).

PCMA asserts that because pharmacy contracts and health plan contracts tie generic drug reimbursements to a specified MAC list, Act 900 substantially impairs those contracts because it requires PBMs to reimburse pharmacies according to the pharmacy’s acquisition cost instead of according to MAC lists and because health plans will have to pay a cost-based price rather than a MAC price. Act 900, however, does not require PBMs to reimburse pharmacies for the price listed on their wholesaler invoices rather than MAC. Acquisition cost is the standard by which an appeal may be initiated, but Act 900 provides that an appeal of a negative MAC reimbursement may be denied if certain criteria are met. Acquisition price becomes the reimbursement standard only if a PBM cannot satisfy section 507(c)(4)(C)(iii). Further, it is undisputed that “pharmacies receive less than their acquisition cost in a very small number of prescriptions dispensed.” PL’s Statement Material Fact ¶ 10; PL’s Resp. Def.’s Statement Material Fact ¶40. Accordingly, Act 900.does not substantially impair preexisting contracts.

Additionally, the appeals procedure imposed by Act 900 does not disrupt reasonable contractual expectations because contracts. between- PBMs and pharmacies generally provide a procedure for appealing MAC reimbursements, PL’s Resp. Def.’s Statement Material Fact ¶ 75; Def.’s Resp. PL’s Statement Material Fact ¶14. Although PBM contracts generally provide that a pharmacist must accept whatever reimbursement a .PBM determines is appropriate based on confidential MAC lists, PL’s Resp. Statement Material Fact ¶ 81, the parties should have reasonably expected an appeals procedure that offered relief from unfair reimbursements; otherwise,, the appeals provisions provided in the parties’ contracts would be a nullity. Indeed, the commonly understood meaning of a “reimbursement” supports this notion. Thus, Act 900 attempts to give effect to terms already embraced by PBM contracts, even if only in theory.

Past industry regulation also suggests that PBMs could not have reasonably expected that their reimbursement practices would escape regulation forever. First, the pharmaceuticals industry is already highly regulated. Bober v. Glaxo Wellcome PLC, 246 F.3d 934, 942 (7th Cir. 2001); see also Energy Reserves Grp., Inc. v. Kansas Power & Light Co., 459 U.S. 400, 413 n.15, 103 S.Ct. 697, 74 L.Ed.2d 569 (1983) (noting as significant that the parties are operating in a heavily regulated industry and that other states regulate certain areas of the industry). Second, Act 900 states that it was enacted to “create accountability in the establishment of prescription drug pricing” and was an obvious attempt to mitigate the harmful results oí MAC pricing. Although Act 900 imposes more specific standards, Act 1194, Act 900’s predecessor, régulated MAC pricing and mandated an appeals process. See S.B. 1138, 89th Gen. Assemb., Reg. Sess. (Ar. 2013). PCMA has also been on notice of the national controversy caused by MAC methodology because other jurisdictions have enacted similar laws regulating PBMs. See Rowe, 429 F.3d at 298, 312-13 (holding Maine’s Unfair Prescription Drug Practices Act was “designed to deal with one of the serious problems of our time,” namely the “tremendous market power” of PBMs and a lack of transparency in their dealings with manufacturers and pharmacies, which ultimately affect pharmaceutical access and cost) (quoting Pharm. Research & Mfrs. of Am. v. Concannon, 249 F.3d 66, 80 (1st Cir. 2001), aff'd sub nom. Pharm. Research & Mfrs. of Am. v. Walsh, 538 U.S. 644, 123 S.Ct. 1855, 155 L.Ed.2d 889 (2003)); Gerhart, 2015 WL 10767327 at *1 (explaining that Iowa law regulates PBMs by overseeing their use of MAC methodology because “pharmacies complain that MAC reimbursements can be so low that pharmacies are forced to sell drugs at a loss or refuse to dispense certain drugs altogether”). As a result, PBMs (cannot be surprised by-.legislative efforts to protect public health and welfare by protecting pharmacies. Cf. Minnesota Ass’n of Health Care Facilities, 742 F.2d at 450 (“Nursing homes could not reasonably expect that the terms of whatever contracts they had with their residents would exempt them from rate regulation by the state.”).

Even if Act 900 substantially impairs preexisting contracts, it still does not,violate the Contract Clause because its purpose, as previously established, is legitimate. See id. at 450-51. It is undisputed that Arkansas pharmacies were in economic distress, that MAC lists are confidential and unregulated, and that contracts allow PBMs to reimburse pharmacies for generic drugs in any manner they see fit. See PL’s Resp. Def.’s Statement Material Fact, ¶¶59, 61, 81. As PCMA asserts, leveling the playing field between contracting parties is not a legitimate purpose, but protecting basic societal interests is. Energy Reserves Group, Inc., 459 U.S. at 412, 103 S.Ct. 697; Janklow, 300 F.3d at 861. The fact that Act 900 may incidentally benefit pharmacies in the process of protecting the public’s ability to access pharmacies does not render the law an insignificant or illegitimate use of the state’s police power. Furthermore, Act 900’s regulations on MAC pricing and appeals procedures are not unreasonable methods of combating MAC reimbursement practices deemed harmful to pharmacies and the public.

The decline-to-dispense provision does not change the outcome because “pharmacies receive less than their acquisition cost in a very small number of prescriptions dispensed.” Pl.’s Statement Material Fact ¶ 10; Pl.’s Resp. Def.’s Statement Material Fact ¶ 40. Act 900 requires PBMs to timely update their MAC lists and to provide an appeals procedure, both of which reduce the likelihood of negative reimbursements even further. Given these considerations, the decline-to-dispense provision does not substantially impair preexisting contractual relationships, nor is it an unreasonable way of accomplishing its legitimate purpose of protecting local pharmacies access.

E. Vagueness Under State and Federal Due Process Clauses

The State of Arkansas’s motion for summary judgment is granted, and PCMA’s motion is denied on PCMA’s facial void-for-vagueness challenge because Act 900 gives fair notice of what is required.

No state can “deprive any person of life, liberty or property, without due process of law.” U.S. Const, amend. XIV, § 1; Ark. Const, art. II, § 8. Statutes violate due process when they fail to sufficiently define prohibited conduct so that a person of ordinary intelligence can understand what conduct is prohibited. Woodis v. Westark Cmty. Coll., 160 F.3d 435, 438 (8th Cir. 1998); Arkansas Tobacco Control Bd. v. Sitton, 357 Ark. 357, 166 S.W.3d 550, 553 (2004). Due process is also violated when statutes establish standards that permit arbitrary or discriminatory enforcement. Woodis, 160 F.3d at 438; Sitton, 166 S.W.3d at 553. A law imposing criminal sanctions or implicating constitutional rights requires more definiteness than a law regulating economic behavior. See Vill. of Hoffman Estates v. Flipside, Hoffman Estates, Inc., 455 U.S. 489, 498, 102 S.Ct. 1186, 71 L.Ed.2d 362 (1982); Ferguson v. Skrupa, 372 U.S. 726, 730, 83 S.Ct. 1028, 10 L.Ed.2d 93 (1963) (legislative bodies have broad scope to experiment with economic problems).

Generally, “[w]hen a state statute is challenged on its face as unconstitutionally vague, and no First Amendment interests are imperiled, that assertion is far too broad.” Reprod. Health Servs. of Planned Parenthood of St. Louis Region, Inc. v. Nixon, 428 F.3d 1139, 1143-44 (8th Cir. 2005). This is because facial challenges “run contrary to the fundamental principle of judicial restraint that courts should neither anticipate a question of constitutional law in advance of the necessity of deciding it nor formulate a rule of constitutional law broader than is required by the precise facts to which it is to be applied.” TCF Nat’l Bank v. Bernanke, 643 F.3d 1158, 1163 (8th Cir. 2011) (citing Wash. State Grange v. Wash. State Republican Party, 552 U.S. 442, 449-50, 128 S.Ct. 1184, 170 L.Ed.2d 151 (2008)); U.S. v. Stephens, 594 F.3d 1033, 1037 (2010) (“Facial challenges threaten to short circuit the democratic process by preventing laws embodying the will of the people from being implemented in a manner consistent with the Constitution.”).

PCMA takes issue with Act 900’s “MAC Update Provision,” which requires a PBM to

Update its Maximum Allowable Cost List on a timely basis, but in no event longer than seven (7) calendar days from an increase of ten percent (10%) or more in the pharmacy acquisition cost from sixty percent (60%) or more of the pharmaceutical wholesaler [sic] doing business in the state....

Ark. Code Ann. § 17-92-501(c)(2). A “pharmaceutical wholesaler” is “a person or entity that sells and distributes prescription pharmaceutical products, including without limitation a full line of brand-name, generic, and over-the-counter pharmaceuticals, and that offers regular and private delivery to a pharmacy.” Id. § 501(a)(2).

According to PCMA, “PBMs have no way to know when their obligations under Act 900’s MAC Update Provision are triggered” because “the statute does not specify whether sixty percent should be calculated by reference to the volume of drug sales or the number of wholesalers.” Pl.’s Mem. Supp. Summ. J., Doc. No. 75-1 at 33. PCMA correctly acknowledges in subsequent briefing, however, that “[t]he plain language of the law requires a PBM to change [its] MAC list when sixty percent of [the] pharmacy wholesalers doing business in Arkansas have an increase in prices” and that the volume of business is “irrelevant” under this language. PL’s Opp. Def.’s Mot. Summ. J., Doc. No. 85 at 37. Thus, PCMA seems to have resolved its vagueness issue, and in any case, the language of the MAC Update Provision is reasonably clear.

To the extent that this language is unclear, no criminal penalties would attach to a PBM in violation of Act 900. This is true because a criminal penalty attaches only if the Arkansas Deceptive Trade Practices Act is violated by a deceptive trade practice that is committed “knowingly and willfully.” Ark. Code Ann. § 4-88-103; see Vill. of Hoffman Estates, 455 U.S. at 499, 102 S.Ct. 1186 (scienter requirement mitigates a law’s vagueness, especially with respect to the adequacy of notice to the complainant that his conduct is proscribed).

PCMA further argues that even if a PBM could determine what constitutes 60% of wholesalers, it still cannot determine what those wholesalers’ prices are because PBMs do not have access to wholesaler price lists. Pl.’s Mem. Supp. Summ. J., Doc. No. 75-1 at 33-34. In addition to implicitly admitting that PBMs can reasonably understand what Act 900 requires of them, this argument does not present an issue of vagueness. Instead, it addresses whether a PBM can comply with Act 900. The question of “vagueness” asks whether the law itself defines illegal behavior sufficiently, Woodis, 160 F.3d at 439, not whether the law provides access to the external information needed to comply-

PCMA further asserts that it cannot comply with Act 900 because gathering the data needed would be an “insurmountable act.” Pl. Resp. Def.’s Statement Material Facts ¶ 72 (undisputed that Optum Rx, a PBM, has not explored the possibility of obtaining a direct data feed with wholesalers). But, MAC “methodologies are based upon the market intelligence that the PBMs have devised as their way of accounting for actual acquisition costs....” Id. ¶ 60. PBMs also have access to wholesale pricing information via Medispan and, in some instances, via automated data feed access directly to individual wholesalers. Id. ¶¶ 69-71. Whether PBMs have the ability to comply with the law’s reasonably clear requirements, though disputed, is not an issue of vagueness and remains to be determined.

IV. CONCLUSION

For these reasons, PCMA’s motion for summary judgment [Doc. No. 75] is granted on PCMA’s ERISA claim because act 900 is invalid as applied to PBMs in their administration and management of ERISA plans. The government’s motion for summary judgment [Doc. No. 77] is granted on all other claims. The joint motions to extend time [Doc. Nos. 103, 104] are denied as moot, and this case is dismissed with prejudice.

IT IS SO ORDERED this 1st day of March 2017.  